I. Yildiz Et Al. , "Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy," 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , vol.31, Illinois, United States Of America, 2013
Yildiz, I. Et Al. 2013. Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).
Yildiz, I., Sen, F., Kilic, L., Keskin, S., Ciftci, R., Ekenel, M., ... Aykan, N. F.(2013). Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy . 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America
Yildiz, İbrahim Et Al. "Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy," 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2013
Yildiz, İbrahim Et Al. "Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2013
Yildiz, I. Et Al. (2013) . "Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy." 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={İbrahim YILDIZ Et Al. }, title={Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy}, congress name={49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2013}}